FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
Trump Administration Plans Chip Tariff Exemptions for Big Tech Amid AI Data Center Push 
Canadian Airlines Suspend Cuba Flights Amid Jet Fuel Shortage and U.S. Sanctions 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
Amazon Explores AI Content Marketplace With Media Publishers 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Lyft Shares Slide After Weak Q1 Profit Forecast and Surprise 2025 Operating Loss 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility 
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year 
Treasury Wine Estates Shares Surge After U.S. Dispute Settlement and Earnings Upgrade 
CAMBRIDGE, Mass., April 09, 2018 -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing neoantigen cancer vaccines, today announced upcoming presentations at the 2018 Annual Meeting of the American Association for Cancer Research (AACR 2018), taking place April 14-18, 2018 in Chicago, IL.
Poster 15: “Neoantigen identification using the ATLAS T cell profiling platform highlights the need to empirically define neoantigens”
Vaccines Session 1, Immunology Track
Sunday, April 15, 2018 from 1 pm to 5 pm CDT
Link to abstract
Poster 5718: “Ex vivo ATLAS-identification of neoantigens for personalized cancer immunotherapy in mouse melanoma”
Neoantigens in Cancer Session, Immunology Track
Wednesday, April 18, 2018 from 8 am to 12 pm CDT
Link to abstract
About Genocea Biosciences, Inc.
Genocea's mission is to help conquer cancer by designing and delivering targeted vaccines and immunotherapies. While traditional immunotherapy discovery methods have largely used predictive methods to propose T cell targets, or antigens, Genocea has developed ATLAS™, its proprietary technology platform, to identify clinically relevant antigens of T cells based on actual human immune responses. Genocea is using ATLAS in immuno-oncology applications to develop neoantigen cancer vaccines, while also exploring partnership opportunities for general cancer vaccines and a vaccine targeting cancers caused by Epstein-Barr Virus. Genocea expects to begin clinical development of its first neoantigen cancer vaccine, GEN-009, in 2018. For more information, please visit www.genocea.com.
Contact:
Jennifer LaVin
207-360-0473
[email protected]
